Please assess the completion status of the following clinical trial:

Trial Title: Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with S. aureus or E. coli bacteriostatic bacteremia defined by at least one positive blood culture bottle~* Patient requiring a blood test as part of his bacteremia~* not subject to a judicial protection measure~* Signature of the non-opposition of consent (for minor patients signed by one of the parents or the representative of the parental authority)~* Affiliation to social security~Exclusion Criteria:~* Immunocompromised patient defined by:~  * current immunosuppressive therapies: corticosteroids, chemotherapy, biotherapy~ * solid organ transplant patient or hematopoietic stem cell transplant~ * chemotherapy-induced neutropenia~ * Congenital immune deficiency~* bacteremia related to a peripheral or central catheter~* Urinary obstruction not lifted within the first 24 hours of management~* Intra-abdominal infection collected undrained in the first 24 hours of management~* primary infectious focus represented by mechanically ventilated pneumonia~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Patients presenting E. coli and S. aureus bacteremia (Type: None): Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia

Based on this trial design, predict the completion outcome and termination type (if applicable).